LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board debut on 5 June to month-end.

Authorised and registered share capital remained unchanged at 74.19 million ordinary shares with a par value of RMB 1 each, comprising 72.93 million H shares listed in Hong Kong and 1.26 million unlisted domestic shares.

No movements occurred in June: issued H shares and unlisted shares were flat at 72.93 million and 1.26 million respectively, with zero treasury shares reported. Consequently, total issued shares stayed at 74.19 million.

Management confirmed that the public float exceeded the Initial Prescribed Threshold of 21.05 percent of issued H shares, satisfying Main Board Rule 13.32B.

The company reported no outstanding share options, warrants, convertible securities or other equity-linked instruments during the period, and affirmed full compliance with all applicable listing and regulatory requirements as of 30 June 2026.